Evidence map›Paper›PMID 25677507›Full record

ArticleProstaglandins & other lipid mediators

Agonists of epoxyeicosatrienoic acids reduce infarct size and ameliorate cardiac dysfunction via activation of HO-1 and Wnt1 canonical pathway.

Jian Cao, Peter L Tsenovoy, Ellen A Thompson, John R Falck, Robert Touchon, Komal Sodhi, Rita Rezzani, Joseph I Shapiro, Nader G Abraham

Open access · greenAbstract read
In one paragraph

Article in Prostaglandins & other lipid mediators. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Jian CaoChinese PLA General Hospital, Beijing 100853, China.
Peter L TsenovoyNew York Medical College, Valhalla, NY, United States.
Ellen A ThompsonJoan C. Edwards School of Medicine, Marshall University, Huntington, WV 25701, United States.
John R FalckUniversity of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, United States.
Robert TouchonJoan C. Edwards School of Medicine, Marshall University, Huntington, WV 25701, United States.
Komal SodhiJoan C. Edwards School of Medicine, Marshall University, Huntington, WV 25701, United States.
Rita RezzaniNew York Medical College, Valhalla, NY, United States.
Joseph I ShapiroJoan C. Edwards School of Medicine, Marshall University, Huntington, WV 25701, United States.
Nader G AbrahamNew York Medical College, Valhalla, NY, United States; Joan C. Edwards School of Medicine, Marshall University, Huntington, WV 25701, United States. Electronic address: Nader_Abraham@NYMC.EDU.
Marshall University · USNew York Medical College · USChinese PLA General Hospital · CNThe University of Texas Southwestern Medical Center · US

Funding

Vasoregulatory Function of CYP2E1-Derived EicosanoidsP01HL034300 · NHLBI · NEW YORK MEDICAL COLLEGE · PI JIANG, HOULI · 1985 to 2015
$33.4M
TRANSPORT EFFECTS OF ARACHIDONATE METABOLITES IN PERFUSED TUBULEP01DK038226 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BROWN, NANCY J. · 1986 to 2015
$22.1M
CORAL: Clinical Coordinating CenterU01HL071556 · NHLBI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI COOPER, CHRISTOPHER J · 2004 to 2013
$19.3M
Receptor Na/K-ATPase Antagonists As Novel Therapeutics For Renal/Cardiac DiseasesR01HL109015 · NHLBI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI SHAPIRO, JOSEPH ISAAC, XIE, ZIJIAN · 2011 to 2014
$2.2M
P450 Arachidonate EpoxygenasesZ01ES025034 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI ZELDIN, DARRYL C · 1995 to 2008
$2.2M
Intramural NIH HHS Z01 ES025034NHLBI NIH HHS HL34300NHLBI NIH HHS HL55601NHLBI NIH HHS P01 HL034300NHLBI NIH HHS R01 HL109015NHLBI NIH HHS U01 HL071556NIDDK NIH HHS P01 DK038226
6 · The paper itself

Abstract

Myocardial infarction (MI) is complicated by ventricular fibrosis and associated diastolic and systolic failure. Emerging studies implicate Wnt1 signaling in the formation of new blood vessels. Epoxyeicosatrienoic acids (EETs)-mediated up-regulation of heme oxygenase-1 (HO-1) protects against the detrimental consequences of MI in several animal models, however, the mechanism(s) by which this occurs remains unclear. The aim of this study was to examine these mechanisms in the LAD ligation animal model of post infarcted heart failure. Specifically, we sought to clarify the mechanistic basis of the interactions of the Wnt1 canonical pathway, HO-1 and associated angiogenesis. Human microvascular endothelial cells (HMECs) were exposed to anoxia and treated with the EET agonist, NUDSA, in the presence and absence of tin mesoporphyrin (SnMP). Increased capillary density, and Wnt1 and HO-1 expression occurred in cells treated with NUDSA. Anoxic HMECs treated with NUDSA and Wnt1 siRNA, exhibited decreased in the expression of β-catenin and the Wnt1 target gene, PPARδ (p<0.05 vs. NUDSA). Furthermore, blocking the Wnt 1 antagonist, Dickkopf 1, by siRNA increased β-catenin and PPARδ expression, and this effect was further enhanced by the concurrent administration of NUDSA. In in vivo experiments, C57B16 mice were divided into 4 groups: sham, mice with MI via LAD ligation and mice with MI treated with NUDSA, with and without SnMP. Increased fractional area change (FAC) and myocardial angiogenesis were observed in mice treated with NUDSA (p<0.05 vs. MI). Increased expression of HO-1, Wnt1, β-catenin, adiponectin, and phospho-endothelial nitric oxide synthetase (p-eNOS), and a decrease in the glycosylated subunit of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, gp91(phox) expression occurred in cardiac tissue of mice treated with NUDSA (p<0.05 vs. MI). SnMP reversed these effects. This novel study demonstrates that increasing the canonical Wnt1 signaling cascade with the subsequent increase in HO-1, adiponectin and angiogenesis ameliorates fibrosis and cardiac dysfunction in a mouse model of MI and supports the hypothesis that HO-1 is an integral component of the EETs-adiponectin axis and is central for the control of resistance to fibrosis and vascular dysfunction and in part determine how they influence the cellular/vascular homeostasis and provides insight into the mechanisms involved in vascular dysfunction as well as potential targets for the treatment of CVD.

Indexed as

AnimalsAspartic AcidCells, CulturedEicosanoidsHeme Oxygenase-1HumansMaleMembrane ProteinsMiceMyocardial InfarctionWnt1 ProteinWnt Signaling Pathway2-(11-(nonyloxy)undec-8-enamido)succinic acidAspartic AcidEicosanoidsHeme Oxygenase-1HMOX1 protein, humanHmox1 protein, mouseMembrane ProteinsWnt1 ProteinWNT1 protein, humanWnt1 protein, mouseAngiogenesisEpoxyeicosatrienoic acidHeme oxygenase-1Myocardial infarctionWnt1

Identifiers

PMID25677507
PMCPMC5553685
OpenAlexW2067879512

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.